Results per Page:
SABCS25: What’s new in breast cancer research?
Advances include a new endocrine therapy, the use of ctDNA to predict response and modifying PET/CTs to better track bone metastases
New clinical trials to target HER2 positive solid cancers
From Dr. Sara Hurvitz, Clinical Research Division, and colleagues
Panorama actual de las tasas de supervivencia del cáncer de mama triple negativo metastásico
Del Laboratorio Hurvitz, División de Investigaciones Clínicas
Current landscape of metastatic triple-negative breast cancer survival rates
From the Hurvitz Lab, Clinical Research Division
American Society of Clinical Oncology honors Fred Hutch and UW hematology-oncology fellows
Five early-career researchers to each receive $50,000 toward innovative cancer research projects
Dr. Sara Hurvitz receives the Smith Family Endowed Chair in Women’s Health
Flexible funding will fuel physician-scientist’s work to improve survivorship for women with cancer
Sacituzumab govitecán para el cáncer de mama metastásico triple negativo
De la Dra. Sara Hurvitz, División de Investigación Clínica
Fred Hutch and UW hematology-oncology fellows win ASCO Young Investigator Awards
Winners represent broad range of research
What’s new in breast cancer research? SABCS 2023 takeaways
New drug combos for metastatic patients and a strong focus on toxicities at San Antonio Breast Cancer Symposium
Dr. Sara Hurvitz joins Fred Hutch, University of Washington
Longtime UCLA breast oncologist and international expert will be senior vice president of the Clinical Research Division